NCT05452525 - Pharmacokinetics and Safety/Tolerability Profile of CKD-379 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

August 27, 2022

Study Completion Date

September 21, 2022

Conditions

Type II Diabetes Mellitus

Interventions

DRUG

CKD-379 I

1 tablet administration under fed condition

DRUG

CKD-379 II

1 tablet administration under fed condition

DRUG

D759+D745+D150

3 tablet coadministration under fed condition

Trial Locations (1)

Seoul National University Hospital, Seoul